CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Inosinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00067327
NCT00067327Phase 2Completed
CompareCT.gov

Treatment of Multiple Sclerosis Using Over the Counter Inosine

National Center for Complementary and Integrative Health (NCCIH)·interventional·Posted Aug 19, 2003·Updated Mar 17, 2006

In Brief

A Phase 2 clinical trial evaluating Inosine for Multiple Sclerosis, Relapsing-Remitting. Completed, across 1 site.

Detailed Summary

The purpose of this study is to determine whether raising low levels of the natural antioxidant uric acid by the administration of a precursor, inosine, has any therapeutic effect on the progression of Relapsing Remitting Multiple Sclerosis (RRMS) and secondary progressive Multiple Sclerosis (MS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis, Relapsing-Remitting
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 19, 2003
Enrollment StartFeb 1, 2002
Study CompletionSep 1, 2005
TodayJul 2, 2026
Posted 22.9 years ago

Interventions

Inosinedrug